Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02035657 | A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma | PHASE1 | COMPLETED | 10 | — | — | Jan 1, 2014 | Mar 1, 2018 | Jun 13, 2018 | 1 | United States |
The number of treatment-related adverse events
| Arm | Type | Description |
|---|---|---|
| GLA-SE | EXPERIMENTAL | Glucopyranosyl Lipid A in Stable Emulsion |
| Name | Type | Description |
|---|---|---|
| GLA-SE | BIOLOGICAL | Glucopyranosyl Lipid A in Stable Emulsion |
Inclusion Criteria: * Biopsy-confirmed Merkel cell carcinoma with metastatic or loco-regional disease. * Patients must have at least one injectable lesion, defined as an easily palpable superficial lesion (cutaneous, subcutaneous or lymph nodal metastasis) that can be accurately localized, stabiliz...